AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$CRL

Andrews Nancy C sold $163K of CRL

Andrews Nancy C sold 573 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $285.24 ($0.16M total) on 2026-08-18.

Original reporting
SEC EDGAR · Andrews Nancy C
Published Aug 20, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CRL
Neutral
high confidence
Mentioned
$CRL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRLNeutralLow
01

Why it matters

The disclosed sale is a routine insider transaction with limited market impact.

02

Market read

Low relevance; the filing is a standard Form 4 disclosure with modest financial magnitude.

03

What to watch

Potential upcoming earnings or regulatory updates that may influence insider behavior.

Relevance 4/10Novelty 4/10Timing: filed 2026-08-20

Background

Charles River Laboratories is a contract research organization providing services to the pharmaceutical and biotech industries.

Company-level read

Ticker impact

$CRLNeutralHigh confidence
Context

Director Nancy Andrews sold 573 shares of Charles River Laboratories for $163,442, reducing her holding to 1,438 shares.

Expected impact

No material price impact expected.

Evidence & confidence

The transaction size is small relative to market cap and typical insider activity, and no broader catalyst is indicated.

Market effects

Sector

None; the sale does not affect the broader healthcare services sector.

Regional

None; limited to a single insider transaction.

Global

None; no global implications.

Counterpoint

What could challenge this read

If the director is reducing exposure due to anticipated negative news, the sale could foreshadow a downside.

Key entities

  • Director
    Nancy Andrews

    Director of Charles River Laboratories who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRL insider trading history →

Related articles

OCT 21
$CRLHigh

Charles River Labs Stock Climbs As Analysts Boost Targets

Charles River Laboratories (CRL) stock rose 11.27% on strong earnings and analyst upgrades. The company reported $1.00B revenue, $150.8M EBITDA, and $148.62M free cash flow. Analysts raised price targets to $320-$357, citing long-term growth plans and margin expansion. CRL's 'Pathway to Purpose' targets 5-7% revenue CAGR and 24% operating margins by 2030.

stockstotrade.com3 min
OCT 21
$CRLHigh

Charles River (CRL) Stock Climbs As Wall Street Turns Bullish

Charles River Laboratories (CRL) stock rose 8.5% on regulatory relief and bullish sentiment. The company's stock broke out of a $290–$310 range, closing near $343. CRL reported $4.0B in annual revenue, with a 32.7% gross margin. Analysts raised price targets, citing margin expansion and growth plans. The next earnings call is scheduled for November 4, 2026.

timothysykes.com3 min
SEP 24
$CRLHighAI 8/10

Why is Charles River Laboratories stock surging today?

Charles River Laboratories (CRL) stock rose 5.7% to $293.22 after its Investor Day, where it unveiled a 'Pathway to Purpose' strategy and raised its 2026 financial outlook. The company set 2030 targets of 5-7% annual organic revenue growth and a 24% non-GAAP operating margin, while reaffirming and upgrading its 2026 guidance. The move was driven by company-specific developments, as the broader market declined.

investing.com2 min
SEP 17
$CRLMed

Why Charles River Laboratories (CRL) Stock Is Trading Up Today

Charles River Laboratories (CRL) shares rose 3.6% after launching rapid cell banking programs, reducing production time by 40% compared to industry standards. The company aims to improve product quality and regulatory readiness. Shares closed at $281.70, up 3% from the previous close. CRL's stock has seen significant volatility, with a 38.1% gain year-to-date.

financialcontent.com2 min